The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Technivie (ombitasvir, paritaprevir, and ritonavir)

What is Technivie?

technivieOn July 24, 2015 the U.S. Food and Drug Administration approved Technivie (ombitasvir, paritaprevir and ritonavir), which is a combination of ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor. Technivie is approved for use in combintation with ribavirin for the treatment of Hepatitis C genotype 4 infections in patients without scarring and poor liver function (cirrhosis). Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy in treating HCV genotype 4 without the need for interferon.

The active ingredients of Technivie are 12.5 mg ombitasvir, 75 mg paritaprevir, and 50 mg ritonavir.

Last Updated: July 2015

Bristol-Myers wins approval for 1st hepatitis C type 3 drug., The Washington Times. Retrieved July 28, 2015.

Highlights of Prescribing Information - TECHNIVIE., AbbVie, Inc. Retrieved July 28, 2015.